Precipitating factors of porphyria cutanea tarda in Brazil with emphasis on hemochromatosis gene (HFE) mutations. Study of 60 patients;Fatores precipitantes na porfiria cutânea tardia no Brasil com ênfase nas mutações do gene (HFE) da hemocromatose. estudo de 60 casos

Anais Brasileiros de Dermatologia

Volumn 88, Issue 4, 2013, Pages 530-540

  Vieira, Fatima Mendonça Jorge ^a   Nakhle, Maria Cristina ^a   Abrantes Lemos, Clarice Pires ^a   Cançado, Eduardo Luiz Rachid ^a   Dos Reis, Vitor Manoel Silva ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hemochromatosis; Hepatitis; Iron overload; Mutation; Porphyria cutanea tarda

Indexed keywords

ESTROGEN; IRON; LIVER ENZYME; PORPHYRIN;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE; GENE MUTATION; HEMOCHROMATOSIS; HEMOCHROMATOSIS GENE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORPHYRIA CUTANEA TARDA; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY;

ADULT; AGE DISTRIBUTION; ALCOHOLISM; CHROMATOGRAPHY, LIQUID; ESTROGENS; FEMALE; GENE FREQUENCY; HEMOCHROMATOSIS; HEPATITIS C; HUMANS; IRON; MALE; MUTATION; PORPHYRIA CUTANEA TARDA; PRECIPITATING FACTORS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SEX DISTRIBUTION;

EID: 84884749857     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/abd1806-4841.20132048     Document Type: Article

References (50)

1. Teubner A, Richter M, Schuppan D, Köstler E, Stölzel U. Hepatitis C, hemochromatosis and porphyria cutanea tarda. Dtsch Med Wochenschr. 2006;131:691-695.
2. Vieira FMJ, Martins JEC. Porphyria cutanea tarda. An Bras Dermatol. 2006;81:573-84.
3. Sixel-Dietrich F, Doss M. Hereditary uroporphyrinogen-decarboxylase deficiency predisposing porphyria cutanea tarda (chronic hepatic porphyria) in females after oral contraceptive medication. Arch Dermatol Res. 1985;278:13-16.
4. Elder GH. Porphyria cutanea tarda. Semin Liver Dis. 1998;18:67-75.
5. Lundvall O. The effect of phlebotomy therapy in porphyria cutanea tarda. Its relations to the phlebotomy-induced reduction of iron stores. Acta Med Scand. 1971;189:33-49.
6. Lundvall O. The effect of replenishment of iron stores after phlebotomy in porphyria cutanea tarda. Acta Med Scand. 1971;189:51-63.
7. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner J P. A porphomethene inhibitor of uro-porphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA. 2007;104:5079-5084.
8. Wallace D F, Subramaniam VN. Co-factors in liver disease: The role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta. 2009;1790:663-670.
9. Gisbert J P, Garcya-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 2003;39:620-627.
10. McAlister F, McCleon K, Hamilton PG, Houston S. Human immunodeficiency virus infection and porphyria cutanea tarda: coexistence of risk factors or causative association? Clin Infect Dis. 1995;20:348-351.
11. Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. 18. Blood. 2000;95:1565-1571.
12. Elder GH, Path MRC, Lee GB, Tovey JA. Decreased activity of hepatic uroporphyrinogen decar-boxylase in sporadic porphyria cutanea tarda. N Engl J Med. 1978;299:274-278.
13. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet. 1996;13:399-408.
14. Batts K P. Iron overload syndromes and the liver. Mod Pathol. 2007;20:S31-S39.
15. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769-1778.
16. Wolff C F, Armas RM, Frank J, Poblete PG. Mutations of hemochromatosis gene in volunteer blood donors and Chilean porphyria cutanea tarda patients. Medicina (B Aires). 2006;66:421-426.
17. Tannapfel A, Stölzel U, Köstler E, Melz S, Richter M, Keim V, et al. C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients. Virchows Arch. 2001;439:1-5.
18. Frank J, Poblete-Gutiérrez P, Weiskirchen R, Gressner O, Merk H F, Lammert F. Hemochromatosis gene sequence deviations in German patients with porphyria cutanea tarda. Physiol Res. 2006;55:S75-83.
19. Cardoso CS, Oliveira P, Porto G, Oberkanins C, Mascarenhas M, Rodrigues P, et al. Comparative study of the two more frequent HFE mutations (C282Y and H63D): significant different allelic frequencies between the North and South of Portugal. Eur J Hum Genet. 2001;9:843-848.
20. Chiavérini C, Halimi G, Ouzan D, Halfon P, Ortonne J P, Lacour J P. Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France. Dermatology. 2003;206:212-216.
21. Brady JJ, Jackson HA, Roberts AG, Morgan RR, Whatley SD, Rowlands GL, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol. 2000;115:868-874.
22. Stuart KA, Busfield F, Jazwinska EC, Gibson P, Butterworth LA, Cooksley WG, et al. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients. J Hepatol. 1998;28:404-409.
23. Martinelli AL, Zago MA, Roselino AM, Filho AB, Villanova MG, Secaf M, et al. Porphyria cutanea tarda in Brazilian patients: association with hemochromatosis C282Y mutation and hepatiits C virus infection. Am J Gastroenterol. 2000;95:3516-3521.
24. Sampietro M, Piperno A, Lupica L, Arosio C, Vergani A, Corbetta N, et al. High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology. 1998;27:181-184.
25. Enriquez de Salamanca R, Morales P, Castro MJ, Rojo R, González M, Arnaiz-Villena A. The most frequent HFE allele linked to porphyria cutanea tarda in Mediterraneans is His63Asp. Hepatology 1999;30:819-820.
26. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human Genome Epidemiology. Am J Epidemiol. 2001;154:193-206.
27. Feder JN, Penny DM, Irrinki A, Lee VK, Lebrón JA, Watson N, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998;95:1472-1477.
28. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology. 2002;122:646-651.
29. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemoch-romatosis: at the crossroads. Gastroenterology. 1999;116:193-207.
30. Cançado RD, Guglielmi ACO, Vergueiro CSV, Rolim EG, Figueiredo MS, Chiattone CS. Study of C282Y, H63D and S65C mutations in the HFE gene in Brazilian patients with iron overload. Rev Bras Hematol Hemoter. 2007;29:351-360.
31. Ferreira ACS, Oliveira VC, Caxito FA, Gomes KB, Castro AM, Pardini VC. Prevalence of C282Y and H63D mutations in the HFE gene of Brazilian individuals with clinical suspicion of hereditary hemochromatosis. Rev Bras Hematol Hemoter. 2008;30:379-383.
32. de Diego C, Opazo S, Murga MJ, Martínez-Castro P. H63D homozygotes with hyperferritinae-mia: Is this genotype the primary cause of iron overload? Eur J Haematol. 2007;78:66-71.
33. Bonini-Domingos CR. Hereditary hemochromatosis and HFE gene mutations. Rev Bras Hematol Hemoter. 2006;28:239-245.
34. Fargion S, Fracanzani AL, Romano R, Cappellini MD, Faré M, Mattioli M, et al. Genetic hemoch-romatosis in Italian patients with porphyria cutanea tarda: possible explanation for iron overload. J Hepatol. 1996;24:564-569.
35. Sampietro M, Fiorelli G, Fargion S. Iron overload in porphyria cutanea tarda. Haematologica. 1999;84:248-253.
36. Pereira AC, Mota G F, Krieger JE. Hemochromatosis gene variants in three different ethnic populations: effects of admixture for screening programs. Hum Biol. 2001;73:145-151.
37. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocya-nate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
38. Lundvall O, Weinfeld A, Lundin P. Iron storage in porphyria cutanea tarda. Acta Med Scand. 1970;1-2:37-53.
39. Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95:1565-1571.
40. Parés A, Barrera JM, Caballería J, Ercilla G, Bruguera M, Caballería L, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology. 1990;12:1295-1299.
41. Mansourati F F, Stone VE, Mayer KH. Porphyria cutanea tarda and HIV/AIDS: a review of patho-genesis, clinical manifestations and management. Int J STD AIDS. 1999;10:51-56.
42. Agostinho MF, Arruda VR, Basseres DS, Bordin S, Soares MC, Menezes RC, et al. Mutation analysis of the HFE gene in Brazilian populations. Blood Cells Mol Dis. 1999;25:324-327.
43. Bueno S, Duch CR, Figueiredo MS. Mutations in the HFE gene (C282Y, H63D, S65C) in a Brazilian population. Rev Bras Hematol Hemoter. 2006;28:293-295.
44. Piperno A, Sampietro M, Pietrangelo A, Arosio C, Lupica L, Montosi G, et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology. 1998;114:996-1002.
45. Toll A, Celis R, Ozalla MD, Bruguera M, Herrero C, Ercilla MG. The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection. J Eur Acad Dermatol Venereol. 2006;20:1201-1206.
46. McDonnell SM, Preston BL, Jewell SA, Barton JC, Edwards CQ, Adams PC, et al. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment. Am J Med. 1999;106:619-624.
47. Seamark CJ, Hutchinson M. Controversy in primary care: should asymptomatic haemochro-matosis be treated? BMJ. 2000;320:1314-1317.
48. Lyon E, Frank EL. Hereditary hemochromatosis since discovery of the HFE gene. Clin Chem. 2001;47:1147-1156.
49. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology. 2001;120:718-725.
50. Gandon Y, Olivié D, Guyader D, Aubé C, Oberti F, Sebille V, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-362.